Is HAE a buy according to AI stock analysis?

HAE AI stock analysis does not label Haemonetics as a straightforward buy because the picture is mixed. The business has a defensible position in blood management and plasma, and the forward P/E of 14.4x appears attractive, but the TTM P/E of 36x, high debt-to-equity of 160%, and dependence on plasma collection volumes mean a buyer needs conviction that the EPS inflection materializes on schedule.

What is the HAE AI stock forecast?

The HAE AI stock forecast uses scenarios, not a guaranteed target. Around the $73.82 cutoff price, the bullish scenario is roughly $104 to $130, the base scenario is roughly $75 to $95, and the bearish scenario is roughly $47 to $62, depending on plasma volume growth, new product adoption, margin execution, and valuation multiples.

What technical levels matter for HAE?

The key HAE technical levels are the $75 to $76 near-resistance zone (20-day MA), the $67 to $69 near-support zone (50-day MA), and the $63 to $65 area (100-day and 200-day MA zone). A close below the 50-day MA would weaken near-term momentum, while a break below the 200-day MA would challenge the longer trend.

Can AI predict HAE stock price?

No, AI cannot reliably predict stock prices. AI can organize filings, market data, valuation math, technical levels, and risk scenarios, but HAE can still move sharply after earnings, FDA decisions, plasma collection volume reports, competitive announcements, hospital budget changes, or macro shocks.

How should I use this HAE AI trading strategy?

Use this HAE AI trading strategy as a research checklist, not a personal instruction. Confirm live price, volume, moving averages, earnings timing, position size, stop level, and portfolio risk before making any trade.

What is the biggest risk in Haemonetics stock analysis?

The biggest risk in Haemonetics stock analysis is that the low forward P/E reflects genuine uncertainty about the earnings recovery. High debt leverage (160% D/E) magnifies any earnings miss, and plasma collection volume depends on donor availability and plasma-derived therapy demand trends that are partly outside management control.

Haemonetics Corporation research snapshot

HAE AI Stock Analysis

HAE AI stock analysis currently reads Haemonetics Corporation as a specialized medical technology company with a defensible position in blood management, plasma collection, and hemostasis. The analysis is not a certain price prediction. At the July 12, 2026 cutoff, the latest verified close used here was $73.82, market capitalization was about $3.36 billion, and the main question was whether plasma volume recovery, new product adoption (SavvyWire, VASCADE MVP), and margin expansion can close the gap between a low forward P/E and a high TTM P/E that reflects recent one-time charges. This is informational research and not investment advice.

Current price

$73.82

Market cap

$3.36 billion

AI score

62 / 100

Rating

Good business, reasonable forward valuation, high debt

Trend status

Above long-term MAs, below short-term MA

Data cutoff (updated weekly)

July 12, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Haemonetics is a mid-cap medical device company with SEC filings, active analyst coverage from BTIG and others, liquid options and stock data, and technical data from multiple public sources.
bias Check: The main AI bias risk is assuming past revenue growth will persist linearly. Plasma volume trends, hospital capital budgets, and competitive dynamics shift. This page separates filing-backed facts from scenario judgments and tracks where data is thin.
ai Confidence: Medium-high data confidence
investment Certainty: Low-medium. HAE has a specialized product portfolio and reasonable forward earnings multiple, but the high debt load, uneven TTM earnings, and dependence on plasma collection volumes add uncertainty.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Haemonetics sells blood management and plasma collection systems with recurring consumable revenue, installed-base service contracts, and a defensible position in hospital hemostasis.	Medium-high
Moat	The moat is built on switching costs from installed plasma and hospital equipment, proprietary disposables, FDA-cleared technology (TEG 6s, VASCADE), and long-term plasma customer relationships.	Medium
Management	Management executed a segment realignment to Apheresis and MedSurg, delivered a Q4 FY26 earnings beat, and earned a BofA upgrade. The track record on capital allocation is still being established.	Medium
Financial trend	Revenue TTM was about $1.33 billion, net income about $97 million. Q4 FY26 showed $346 million revenue and $60 million net income. Levered free cash flow was strong at roughly $298 million.	Medium-high
Valuation	The stock trades at 36x TTM earnings but only 14.4x forward earnings, reflecting a sharp EPS inflection expected in FY2027. EV/EBITDA is 16.4x and FCF yield is about 8.9%.	Medium
Technical trend	HAE trades above its 50-day ($67.51), 100-day ($63.78), and 200-day ($65.37) MAs but below the 20-day MA ($75.22), indicating a short-term pullback in a broader uptrend.	Medium-high
Risk level	Key risks are high debt-to-equity (160%), plasma collection volume dependence, hospital capital spending cycles, FDA regulatory exposure, and competitive pressure in vascular closure.	Medium-high
AI confidence	Medium-high confidence for the business description, latest filings, market cap math, and major risk categories. Lower confidence for precise near-term revenue or earnings forecasts.	Medium-high data confidence
Investment certainty	Low-medium certainty. The forward earnings setup looks attractive if FY2027 EPS materializes, but execution risk and debt leverage limit conviction.	Low-medium

HAE AI stock forecast

HAE AI Stock Forecast Scenarios

The HAE AI stock forecast uses scenario ranges around the $73.82 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires sustained plasma volume growth, SavvyWire and VASCADE MVP adoption, margin expansion, and debt reduction. The base case assumes gradual volume recovery with steady margins. The bearish case assumes macro pressure on hospital spending, competitive losses, or plasma collection disruption.

Bullish case

$104 to $130

More likely if HAE sustends double-digit EPS growth through plasma volume recovery, SavvyWire gains share in TAVR, VASCADE MVP becomes a standard closure device, and operating margins expand from recent levels.

Base case

$75 to $95

More likely if EPS grows at a high single digit pace, revenue tracks long-term medical device trends, and the forward P/E settles near 16 to 18x.

Bearish case

$47 to $62

More likely if hospital capital budgets tighten, plasma collections decline, regulatory headwinds emerge for any product line, or the high debt load constrains strategic flexibility and the stock re-rates to 10 to 12x forward earnings.

HAE AI technical analysis

HAE AI Technical Analysis

HAE AI technical analysis starts from the $73.82 close used for this July 12 static page. Public technical sources showed the stock above its 50-day, 100-day, and 200-day moving averages but below the 20-day average, reflecting a short-term pullback. The 14-day RSI was near 60.7, neutral area. ADX above 25 indicated a trending environment. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.

Level	Value	Why it matters
Current price	$73.82	Latest verified close used for this page as of the July 12, 2026 data cutoff.
Near support	$67 to $69	Support zone around the 50-day moving average ($67.51) reported by Barchart.
Secondary support	$63 to $65	The 100-day and 200-day moving average area ($63.78 and $65.37). A sustained break below the 200-day MA would weaken the long-term technical picture.
Near resistance	$75 to $76	The 20-day moving average area ($75.22). A close above this level with volume would signal short-term momentum recovery.
52-week high	$87.32	The upper bound of the past 52 weeks. A breakout above this level would signal a new uptrend leg.
50-day moving average	$67.51	Barchart showed HAE above the 50-day MA around the cutoff, supporting the medium-term trend.
200-day moving average	$65.37	Public technical sources showed HAE above its 200-day MA, supporting the long trend.
Momentum	RSI 60.67, ADX 26.43	RSI was neutral-bullish. ADX above 25 indicated a trending environment, not a range-bound one.
Volume	About 483,000 shares	The recent volume snapshot was below the average of about 900,000, suggesting cautious participation.
Volatility	ATR 14 near $2.83 (3.71%)	Position sizing should allow for normal daily movement of around 3.7% at the cutoff price.
Invalidation	Close below $67, then $65	A close below the 50-day MA weakens the near-term setup. A break below the 200-day area would challenge the long trend.

HAE AI trading strategy

HAE AI Trading Strategy Framework

The HAE AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.

Trend-following setup

Look for HAE to hold above the 50-day area ($67) and reclaim the 20-day MA ($75) with improving volume before treating momentum as confirmed.

A daily close below the 50-day MA without quick recovery should reduce confidence in the near-term trend.

Mean-reversion setup

If HAE pulls back toward the 50-day or 200-day MA zone without fundamental deterioration, compare the entry with upcoming earnings, plasma volume data, and product adoption trends.

Do not average down solely because the forward P/E is low. Verify that the thesis drivers (plasma, SavvyWire, margins) remain intact.

Fundamental monitor

Track quarterly earnings, plasma collection volume trends, SavvyWire and VASCADE revenue growth, debt repayment progress, and segment margin changes in the new Apheresis and MedSug reporting structure.

Lower the rating if free cash flow weakens while debt stays elevated, or if competitive pressure in vascular closure intensifies.

Investment research summary

Four-master Research Compression

Business essence

Haemonetics provides medical devices and software for blood plasma collection, hospital hemostasis monitoring, surgical blood recovery, and vascular closure. Recurring consumable and service revenue from installed systems creates an annuity-like base.

Moat

The moat comes from regulatory-cleared installed equipment, proprietary single-use disposables, long-standing plasma customer contracts, and the TEG 6s brand in viscoelastic testing for bleeding management.

Munger risk inversion

The thesis can fail if plasma collection volumes decline, hospital capital budgets compress, competitive products erode VASCADE or SavvyWire share, or the high debt load (160% D/E) restricts reinvestment.

Management

Management recently realigned the company into Apheresis and MedSurg segments and delivered a Q4 beat. The BofA upgrade after earnings signals improving credibility. The capital allocation track record is still being built.

Industry trend

Haemonetics sits at the intersection of plasma-derived therapies, hospital patient blood management, and minimally invasive surgical closure. Plasma demand is structurally supported by growing immunoglobulin use, while hospital focus on bleeding management is secular.

Valuation and margin of safety

At 36.0x TTM PE but 14.4x forward PE, the stock prices in a significant EPS recovery. The 8.9% FCF yield provides some buffer, but the high debt and uneven earnings history mean the margin of safety depends on delivery of FY2027 estimates.

Source-backed data

HAE Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
HAE price	$73.82 close on July 8, 2026	Yahoo Finance	July 12, 2026
Market capitalization	$3.36 billion, verified as $73.82 x 45.45M shares	financial_rigor.py market cap verification and Yahoo Finance	July 12, 2026
Revenue TTM	$1.33 billion	Yahoo Finance statistics	July 12, 2026
Net income TTM	$97.3 million	Yahoo Finance statistics	July 12, 2026
Diluted EPS TTM	$2.05	Yahoo Finance statistics	July 12, 2026
Forward P/E	14.39x	Yahoo Finance statistics	July 12, 2026
Levered free cash flow TTM	$298.09 million	Yahoo Finance statistics and financial_rigor.py	July 12, 2026
Cash and cash equivalents	$246.26 million	Yahoo Finance balance sheet	July 12, 2026
Total debt / equity	160.08%	Yahoo Finance statistics	July 12, 2026
Valuation math	36.01x TTM PE, 14.39x forward PE, 4.28x PB, 11.25x P/FCF, 8.89% FCF yield from financial_rigor.py	financial_rigor.py valuation verification	July 12, 2026
Moving averages and momentum	50-day MA $67.51, 200-day MA $65.37, 14-day RSI 60.67, ADX 26.43	Barchart technical analysis	July 12, 2026
Q4 FY26 quarterly revenue and earnings	Revenue $346.35 million, net income $59.73 million	Yahoo Finance earnings data	July 12, 2026

Frequently Asked Questions

Read the AAPL AI stock analysis View the NVDA AI stock forecast Explore the AI Stock Picker Generate an AI trading strategy

This HAE AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong.